<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">World J Surg Oncol</journal-id><journal-id journal-id-type="iso-abbrev">World J Surg Oncol</journal-id><journal-title-group><journal-title>World Journal of Surgical Oncology</journal-title></journal-title-group><issn pub-type="epub">1477-7819</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27102733</article-id><article-id pub-id-type="pmc">PMC4840965</article-id><article-id pub-id-type="publisher-id">877</article-id><article-id pub-id-type="doi">10.1186/s12957-016-0877-6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Recurrences in stage II rectal carcinoma after curative resection alone: from the viewpoint of angiogenesis</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Martinovi&#x00107;</surname><given-names>&#x0017d;eljko</given-names></name><address><email>zeljko.martinovic3@gmail.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Kova&#x0010d;</surname><given-names>Dra&#x0017e;en</given-names></name><address><email>drazen.kovac@medri.uniri.hr</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Martinovi&#x00107;</surname><given-names>Cvita</given-names></name><address><email>cvita.martinovic@gmail.com</email></address><xref ref-type="aff" rid="Aff3"/></contrib><aff id="Aff1"><label/>Department of Surgery, Croatian Hospital &#x0201c;Dr. Fra Mato Nikoli&#x00107;&#x0201d;, 72 276 Nova Bila, Bosnia and Herzegovina </aff><aff id="Aff2"><label/>Department of Pathology, School of Medicine, University of Rijeka, 51 000 Rijeka, Croatia </aff><aff id="Aff3"><label/>Department of Internal Medicine, Croatian Hospital &#x0201c;Dr. Fra Mato Nikoli&#x00107;&#x0201d;, 72 276 Nova Bila, Bosnia and Herzegovina </aff></contrib-group><pub-date pub-type="epub"><day>22</day><month>4</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>22</day><month>4</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>14</volume><elocation-id>122</elocation-id><history><date date-type="received"><day>7</day><month>7</month><year>2015</year></date><date date-type="accepted"><day>15</day><month>4</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; Martinovi&#x00107; et al. 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Angiogenesis plays a pivotal role in malignant tumor progression. The count of blood microvessels of the tumor has been recognized as an indicator of malignant potential of the tumors and provides the ability to predict tumors recurrence. The role endoglin in the Dukes B rectal cancer is still unexplored. The aims of this study were to examine immunohistochemical expression of endoglin in resected rectal cancer and investigate the relationship of tumor recurrence and other clinicopathological variables to the endoglin-assessed microvessel density of the tumor tissue and distal resection margins.</p></sec><sec><title>Methods</title><p>The study included 95 primary rectal adenocarcinomas, corresponding to 95 distal and 95 proximal resection margin specimens from surgical resection samples. Tumor specimens were paraffin embedded, and immunohistochemical staining for the CD105 endothelial antigen was performed to count CD105-MVD. For exact measurement of the CD105-MVD used, a computer-integrated system Alphelys Spot Browser 2 was used.</p></sec><sec><title>Results</title><p>The MVD was significantly higher in the tumor samples compared with the distal resection margins (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001) and the proximal resection margins (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001). There was no significant difference in the MVD between distal and proximal resection margins (<italic>p</italic>&#x02009;=&#x02009;0.147). The type of surgical resection was a significant factor for determining the recurrence of tumors (<italic>p</italic>&#x02009;=&#x02009;0.0104). There was no significant effect of patients&#x02019; age, gender, tumor location, grade of differentiation, histological tumor type, and the size and depth of tumor invasion on the recurrence of the tumor. The recurrence rate was significantly higher in the low CD105-MVD group of patients than in the high CD105-MVD group of patients (log rank test, <italic>p</italic>&#x02009;=&#x02009;0.0406). Result of the multivariate analysis showed that the type of surgery (<italic>p</italic>&#x02009;=&#x02009;0.0086), MVD tumors (<italic>p</italic>&#x02009;=&#x02009;0.0385), and MVD of proximal resection margin (<italic>p</italic>&#x02009;=&#x02009;0.0218) were the independent prognostic factors for the recurrent tumors.</p></sec><sec><title>Conclusions</title><p>CD105-assessed MVD could help to identify patients with more aggressive disease and increased risk of developing tumor recurrence after surgical treatment in stage II rectal cancer (RC).</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Rectal cancer</kwd><kwd>Angiogenesis</kwd><kwd>Microvessel density</kwd><kwd>Endoglin</kwd><kwd>Recurrence</kwd></kwd-group><funding-group><award-group><funding-source><institution>Zeljko Martinovic</institution></funding-source><award-id>1</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Background</title><p>Radical surgical treatment of stage II rectal cancer (RC) is surgical challenge associated with high risk of recurrence of the tumor [<xref ref-type="bibr" rid="CR1">1</xref>]. After total mesorectal excision surgery with intent, despite the absence of nodal disease, 25&#x000a0;% of these patients will relapse within 5&#x000a0;years [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. Recurrence of the tumor is an adverse prognostic indicator with a poor overall survival prognosis [<xref ref-type="bibr" rid="CR4">4</xref>]. The risk of relapse may be estimated by assessing the clinical and histopathological features of the cancer [<xref ref-type="bibr" rid="CR5">5</xref>].</p><p>Tumor growth and its spread to adjacent tissue depend on its ability to stimulate angiogenesis. Angiogenesis consists of formation of new blood vessels from pre-existing vasculature [<xref ref-type="bibr" rid="CR6">6</xref>]. The studies have shown that the angiogenic potential of a tumor may be inferred from its vascularity measured in histological section [<xref ref-type="bibr" rid="CR7">7</xref>]. The count of blood microvessels of the tumor, as shown in microvessel density (MVD), has been recognized as an indicator of malignant potential of the tumors and provides the ability to predict tumor recurrence and survival. Endoglin (CD105) has been suggested to be the most suitable marker available to quantify tumor angiogenesis [<xref ref-type="bibr" rid="CR8">8</xref>].</p><p>Our study aimed to examine immunohistochemical expression of CD105 in stage II RC and to investigate a correlation between CD105-assessed MVD and clinicopathological variables and to analyze prognostic value of MVD on the tumor recurrence.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Patients and specimens</title><p>We studied 95 cases of primary rectal adenocarcinomas in stage II (T3&#x02013;T4, N0, M0) treated by complete surgical resection (R0) in a 5-year period at Clinic for Surgery, Clinical Hospital Center Rijeka, Croatia, from January 2002 to December 2006. The study included 95 primary rectal adenocarcinomas, 95 surgical distal resection margin specimens, and 95 surgical proximal resection margin specimens from surgical resection samples. The distal resection margin (DRM) and proximal resection margin (PRM) corresponding to the primary tumor from the same patients was taken from the margin of near and distant surgical resection. Tissue samples included in this study were retrieved from the archives of the Institute of Pathology School of Medicine of Rijeka, Croatia. The exclusion criteria were a synchronous tumor or tumors in another localization in anamnesis, emergency surgery, preoperative radiotherapy or chemotherapy, perforation of bowel, and incomplete clinical data. The study was approved by the University of Rijeka Ethics Committee and patients signed informed consent.</p><p>All of the patients underwent radical low anterior resection (LAR) or abdominoperineal resection (APR). All patients had confirmed rectal adenocarcinomas by histopathology and were staged according to the 7th edition of the American Joint Committee on Cancer Staging Manual [<xref ref-type="bibr" rid="CR9">9</xref>]. The histological grading was classified according to the World Health Organization (WHO) classification [<xref ref-type="bibr" rid="CR10">10</xref>]. The mean duration of follow-up was 54.7&#x02009;&#x000b1;&#x02009;23.1&#x000a0;months (median duration, 60.0&#x000a0;months) after the operation for RC. Recurrence data and cause of death of those who died during follow-up period were obtained from the Croatian Cancer Registry. Patient and tumor characteristics are presented in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Clinical and pathologic characteristics of the rectal cancer samples</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Characteristics</th><th>Number of patients</th></tr></thead><tbody><tr><td>Total number</td><td>95</td></tr><tr><td colspan="2">Age, median 69&#x000a0;years</td></tr><tr><td>&#x02003;&#x02264;69</td><td>49</td></tr><tr><td>&#x02003;&#x0003e;69</td><td>46</td></tr><tr><td colspan="2">Gender</td></tr><tr><td>&#x02003;Male</td><td>61</td></tr><tr><td>&#x02003;Female</td><td>34</td></tr><tr><td colspan="2">Type of surgery</td></tr><tr><td>&#x02003;Low anterior resection</td><td>76</td></tr><tr><td>&#x02003;Abdominoperineal resection</td><td>19</td></tr><tr><td colspan="2">Tumor location</td></tr><tr><td>&#x02003;Upper rectum</td><td>23</td></tr><tr><td>&#x02003;Middle rectum</td><td>52</td></tr><tr><td>&#x02003;Low rectum</td><td>20</td></tr><tr><td colspan="2">Grade of differentiation</td></tr><tr><td>&#x02003;G1</td><td>55</td></tr><tr><td>&#x02003;G2</td><td>34</td></tr><tr><td>&#x02003;G3</td><td>6</td></tr><tr><td colspan="2">Histologic type</td></tr><tr><td>&#x02003;Adenocarcinoma</td><td>82</td></tr><tr><td>&#x02003;Adenocarcinoma with mucinous features</td><td>13</td></tr><tr><td colspan="2">Depth of tumor invasion</td></tr><tr><td>&#x02003;T3</td><td>37</td></tr><tr><td>&#x02003;T4a</td><td>42</td></tr><tr><td>&#x02003;T4b</td><td>16</td></tr><tr><td colspan="2">Tumor size</td></tr><tr><td>&#x02003;&#x02264;4&#x000a0;cm</td><td>64</td></tr><tr><td>&#x02003;&#x0003e;4&#x000a0;cm</td><td>31</td></tr><tr><td colspan="2">Tumor recurrence</td></tr><tr><td>&#x02003;Yes</td><td>16</td></tr><tr><td>&#x02003;No</td><td>79</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec4"><title>Immunohistochemistry</title><p>Immunohistochemical analysis was performed on formalin-fixed paraffin-embedded section. All tissue samples from RC, DRM, and PRM were fixed in 10&#x000a0;% buffered formalin and embedded in paraffin. We prepared 4-&#x003bc;m-thick serial section which were deparaffinized in xylene, rehydrated in graded ethanol, and washed with phosphate-buffered saline. Endogenous peroxidase was inhibited with 3&#x000a0;% hydrogen peroxide. Tissue sections were incubated for 30&#x000a0;min with the anti-CD105 primary monoclonal antibody (mouse anti-human, clone SN6h, Dako Corporation, Denmark) at a 1:10 dilution. Primary antibody binding site was visualized using a secondary antibody detection kit (Envision + kit; Dako, Denmark).</p><p>The staining was visualized with diaminobenzidine (DAB). Tissue sections were counterstained with hematoxylin. Brown staining for CD105 was considered positive. Distant normal mucosa free of tumor were used as positive controls, and the primary antibody was replaced with phosphate-buffered saline solution for negative controls.</p></sec><sec id="Sec5"><title>Evaluation of staining and of MVD by computerized image analysis</title><p>All slides stained with anti-CD105 were viewed and analyzed with Alphelys Spot Browser 2 integrated system, using a software controlled (Alphelys Spot Browser 2.4.4., France) stage positioning Nikon Eclipse 50i microscope mounted 1360&#x02009;&#x000d7;&#x02009;1024 resolution Microvision CFW-1310C digital camera. The slides were scanned at &#x000d7;20 magnification to identify &#x0201c;hot spots&#x0201d; (areas with the highest microvessel concentration) for the slides and then &#x000d7;200 magnification to create images for quantification scoring positive cells and MVD. Positive cells were counted in the tumor, DRM, and PRM and presented as percentage of positive cells and MVD as number of microvessels in the histological field according to Weidner et al. [<xref ref-type="bibr" rid="CR11">11</xref>]. The regions with the most intensive vascularization (hot spots) were defined by scanning the entire tumor section at low magnification with a selection of four fields. The areas of this histological field was 0.612&#x000a0;mm<sup>2</sup>. Hot spots were identified by two independent observers at &#x000d7;20 magnification.</p></sec><sec id="Sec6"><title>Statistical analysis</title><p>Statistical analysis was performed using MedCalc version 14.8.1 (MedCalc Software bvba, Mariakerke, Belgium). Descriptive statistics and 95&#x000a0;% confidence intervals were calculated to describe data. The distribution of data was tested for normality using the Smirnov-Kolmogorov test. The Mann-Whitney <italic>U</italic> test and Kruskal-Wallis tests were used to compare MVD among the clinicopathological variables. Spearman&#x02019;s rho correlation was used to test the correlation between the immunohistochemical findings and tumor recurrence. The receiver operating characteristic (ROC) curve approach was used to determine best-fitting cut-off for the MVD in terms of the tumor recurrence analysis [<xref ref-type="bibr" rid="CR12">12</xref>]. Tumor recurrence analysis was estimated by the Kaplan-Meier method and compared by the log rank test. Prognostic factors of tumor recurrence were identified by the use of the Cox proportional hazard regression. Differences at <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 were considered significant.</p></sec></sec><sec id="Sec7"><title>Results</title><sec id="Sec8"><title>Patient sample classification</title><p>We assessed paraffin-embedded specimens from tumors from the 95 patients resected for RC. Clinicopathological characteristics of patients are summarized in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. The median age at diagnosis was 69&#x000a0;years (range 15 to 85&#x000a0;years), 49 patients (51.6&#x000a0;%) were &#x02264;69&#x000a0;years of age, and 46 patients (48.4&#x000a0;%) were &#x0003e;69&#x000a0;years old. Sixty-one (64.2&#x000a0;%) were males and 34 (35.8&#x000a0;%) were females. In 23 patients (24.2&#x000a0;%), the tumor was located in the upper rectum, in 52 (54.7&#x000a0;%), in the middle rectum and in 20 (21.1&#x000a0;%), in the low rectum. According to the grade of differentiation, 55 patients (57.9&#x000a0;%) were G1 (well differentiated), 34 (35.8&#x000a0;%) G2 (moderately differentiated), and 6 (6.3&#x000a0;%) G3 (poorly differentiated). According to the depth of tumor invasion, 37 patients (38.9&#x000a0;%) were T3, 42 (44.2&#x000a0;%) T4a, and 16 (16.9&#x000a0;%) T4b. Eighty-two (86.3&#x000a0;%) tumors were classified as adenocarcinomas and 13 (13.7&#x000a0;%) as adenocarcinomas with mucinous features. Median tumor size was 3.8&#x000a0;cm (range, 1.3 to 12.0&#x000a0;cm). The median patients follow-up was 60&#x000a0;months (range, 1.0 to 109.0&#x000a0;months). Of the 95 patients, 16 patients developed recurrence of the tumor (recurrence rate, 16.8&#x000a0;%) and 29 died of RC (overall survival rate, 30.5&#x000a0;%) in the 5-year follow-up period.</p></sec><sec id="Sec9"><title>Microvessel density</title><p>MVD were analyzed in tumors, distal resection margins, and proximal resection margins. Examples of CD105 expression in the tumor samples, distal resection margins, and the proximal resection margins are shown in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>. Median CD105-assessed MVD in tumors was 174.47 vessels/mm<sup>2</sup> (95 % CI 151.00&#x02013;205.29), distal resection margins 89.86 vessels/mm<sup>2</sup> (95 % CI 55.46&#x02013;103.80), and the proximal resection margins 58.82 vessels/mm<sup>2</sup> (95 % CI 51.42&#x02013;82.56). The MVD was significantly higher in the tumor samples compared with distal resection margins (Wilcoxon test, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001) and the proximal resection margins (Wilcoxon test, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). There was no significant difference in the MVD between distal and proximal resection margins (Wilcoxon test, <italic>p</italic>&#x02009;=&#x02009;0.147). We found that CD105-MVD in tumor tissue (rho&#x02009;=&#x02009;&#x02212;0.321, <italic>p</italic>&#x02009;=&#x02009;0.0015, 95 % CI &#x02212;.491 to &#x02212;1.128) and proximal resection margins (rho&#x02009;=&#x02009;&#x02212;0.220, <italic>p</italic>&#x02009;=&#x02009;0.0324, 95 % CI &#x02212;0.403 to &#x02212;0.019) correlated inversely with tumor recurrence rate. On the other hand, CD105-MVD in distal resection margins (rho&#x02009;=&#x02009;0.312, <italic>p</italic>&#x02009;=&#x02009;0.0021, 95 % CI 0.118 to 0.483) correlated positively with tumor recurrence rate. There was statistically significant correlation between CD105-MVD in tumor (&#x02264;106.2 vessels/mm<sup>2</sup>/&#x0003e;106.2 vessels/mm<sup>2</sup>) (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3a</xref>; <italic>p</italic>&#x02009;=&#x02009;0.0037), CD105-MVD in DRM (&#x02264;186.3 vessels/mm<sup>2</sup>/&#x0003e;186.3 vessels/mm<sup>2</sup> (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3b</xref>; <italic>p</italic>&#x02009;=&#x02009;0.0076), CD105-MVD in PRM (&#x02264;27.8 vessels/mm<sup>2</sup>/&#x0003e;27.8 vessels/mm<sup>2</sup>) (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3c</xref>; <italic>p</italic>&#x02009;=&#x02009;0.0490), and tumor recurrence as determined by Fisher&#x02019;s exact test.<fig id="Fig1"><label>Fig. 1</label><caption><p>Immunohistochemical staining for the CD105 endothelial antigen in the tumor samples (<bold>a</bold>), distal resection margins (<bold>b</bold>), and the proximal resection margins (<bold>c</bold>). Magnification &#x000d7;200</p></caption><graphic xlink:href="12957_2016_877_Fig1_HTML" id="MO1"/></fig><fig id="Fig2"><label>Fig. 2</label><caption><p>Box-and-whisker plots of CD105-MVD in tumors, distal resection margins, and proximal resection margins. The CD105-MVD level was significantly higher in the tumor compared with the distal resection margin (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) and the proximal resection margin (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001). In these box plots, median values are represented by <italic>lines within the boxes</italic>, <italic>whiskers</italic> represent the interquartile range, and outliers are represented as individual data points</p></caption><graphic xlink:href="12957_2016_877_Fig2_HTML" id="MO2"/></fig><fig id="Fig3"><label>Fig. 3</label><caption><p>Correlation analysis between tumor recurrence and CD105-MVD in tumor, distal and proximal resection margin. <bold>a</bold> Recurrence and CD105-MVD in tumor (<italic>p</italic>&#x02009;=&#x02009;0.0037). <bold>b</bold> Recurrence and CD105-MVD in DRM (<italic>p</italic>&#x02009;=&#x02009;0.0076). <bold>c</bold> Recurrence and CD105-MVD in PRM (<italic>p</italic>&#x02009;=&#x02009;0.0490)</p></caption><graphic xlink:href="12957_2016_877_Fig3_HTML" id="MO3"/></fig></p></sec><sec id="Sec10"><title>Univariate recurrence analysis</title><p>The Kaplan-Meier method and log-rank test were performed. In the univariate analysis (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>), the type of surgical resection was a significant factor for determining the recurrence of tumors (log-rank test, <italic>p</italic>&#x02009;=&#x02009;0.0104) (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>). There was no significant effect of patients&#x02019; age, gender, tumor location, grade of differentiation, histological tumor type, the size and depth of tumor invasion on the recurrence of the tumor.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Univariate analysis for tumor recurrence</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>Hazard ratio</th><th>95&#x000a0;% CI</th><th>
<italic>p</italic> value*</th></tr></thead><tbody><tr><td>Age (median)</td><td/><td/><td>0.716</td></tr><tr><td>&#x02003;&#x02264;69</td><td>1.000</td><td/><td/></tr><tr><td>&#x02003;&#x0003e;69</td><td>0.839</td><td>0.310&#x02013;2.268</td><td/></tr><tr><td>Gender</td><td/><td/><td>0.142</td></tr><tr><td>&#x02003;Male</td><td>1.000</td><td/><td/></tr><tr><td>&#x02003;Female</td><td>0.426</td><td>0.152&#x02013;1.190</td><td/></tr><tr><td>Type of surgery</td><td/><td/><td>0.010</td></tr><tr><td>&#x02003;Low anterior resection</td><td>1.000</td><td/><td/></tr><tr><td>&#x02003;Abdominoperineal resection</td><td>3.140</td><td>0.919&#x02013;10.725</td><td/></tr><tr><td>Tumor location</td><td/><td/><td>0.710</td></tr><tr><td>&#x02003;Upper rectum</td><td>1.000</td><td/><td/></tr><tr><td>&#x02003;Middle rectum</td><td>1.267</td><td>0.381&#x02013;4.213</td><td/></tr><tr><td>&#x02003;Low rectum</td><td>1.716</td><td>0.419&#x02013;7.026</td><td/></tr><tr><td>Grade of differentiation</td><td/><td/><td>0.936</td></tr><tr><td>&#x02003;G1</td><td>1.000</td><td/><td/></tr><tr><td>&#x02003;G2</td><td>1.933</td><td>0.416&#x02013;3.423</td><td/></tr><tr><td>&#x02003;G3</td><td>1.119</td><td>0.137&#x02013;9.137</td><td/></tr><tr><td>Histologic type</td><td/><td/><td>0.299</td></tr><tr><td>&#x02003;Adenocarcinoma</td><td>1.000</td><td/><td/></tr><tr><td>&#x02003;Adenocarcinoma with mucinous features</td><td>0.381</td><td>0.096&#x02013;1.514</td><td/></tr><tr><td>Depth of tumor invasion</td><td/><td/><td>0.925</td></tr><tr><td>&#x02003;T3</td><td>1.000</td><td/><td/></tr><tr><td>&#x02003;T4a</td><td>0.919</td><td>0.316&#x02013;2.673</td><td/></tr><tr><td>&#x02003;T4b</td><td>0.745</td><td>0.172&#x02013;3.223</td><td/></tr><tr><td>Tumor size</td><td/><td/><td>0.329</td></tr><tr><td>&#x02003;&#x02264;4&#x000a0;cm</td><td>1.000</td><td/><td/></tr><tr><td>&#x02003;&#x0003e;4&#x000a0;cm</td><td>0.594</td><td>0.214&#x02013;1.651</td><td/></tr></tbody></table><table-wrap-foot><p>
<italic>95&#x000a0;% CI</italic> confidence interval</p><p>*log-rank test</p></table-wrap-foot></table-wrap><fig id="Fig4"><label>Fig. 4</label><caption><p>Kaplan-Meier curves for recurrence-free survival according to the type of surgery. <italic>Solid line</italic>, patients with LAR. <italic>Dotted line</italic>, patients with APR</p></caption><graphic xlink:href="12957_2016_877_Fig4_HTML" id="MO4"/></fig></p><p>The cut-off value for determining high and low MVD with respect to recurrent tumor was performed by the receiver operating characteristic (ROC) curve analysis. The cut-off value for MVD in tumors, distal and proximal resection margins were &#x02264;106.2 microvessel/mm<sup>2</sup> (sensitivity 56.2&#x000a0;%, specificity 81.0&#x000a0;%), &#x0003e;186.3 microvessel/mm<sup>2</sup> (sensitivity 37.5&#x000a0;%, specificity 91.1&#x000a0;%), and &#x02264;27.8 (sensitivity 43.7&#x000a0;%, specificity 81.0&#x000a0;%), respectively (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). The cut-off values for MVD in the primary tumors, distal resection margins, and proximal resection margins are shown in Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Optimal cut-off point of CD105-MVD in tumors, distal resection margins, and proximal resection margins</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variables</th><th>AUC</th><th>Cut-off value</th><th>Sensitivity</th><th>Specificity</th></tr></thead><tbody><tr><td>MVD in tumors</td><td char="." align="char">0.601</td><td char="." align="char">106.2</td><td char="." align="char">56.2</td><td char="." align="char">81.0</td></tr><tr><td>MVD in DRM</td><td char="." align="char">0.656</td><td char="." align="char">186.3</td><td char="." align="char">37.5</td><td char="." align="char">91.1</td></tr><tr><td>MVD in PRM</td><td char="." align="char">0.602</td><td char="." align="char">27.8</td><td char="." align="char">43.7</td><td char="." align="char">81.0</td></tr></tbody></table><table-wrap-foot><p>
<italic>AUC</italic> area under the curve</p></table-wrap-foot></table-wrap><fig id="Fig5"><label>Fig. 5</label><caption><p>Receiver operating characteristic (ROC) curve analysis for optimal cut-off point of CD105-MVD. <bold>a</bold> Cut-off value of MVD in tumor 106.2/mm<sup>2</sup>. <bold>b</bold> Cut-off value of MVD in DRM 186.3/mm<sup>2</sup>. <bold>c</bold> Cut-off value of MVD in PRM 27.8/mm<sup>2</sup>
</p></caption><graphic xlink:href="12957_2016_877_Fig5_HTML" id="MO5"/></fig></p><p>In a Kaplan-Meier recurrence of tumors estimate (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>), tumor with a low MVD (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6a</xref>, log-rank test, <italic>p</italic>&#x02009;=&#x02009;0.0008) and tumor with low MVD proximal resection margin (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6b</xref>, log-rank test, <italic>p</italic>&#x02009;=&#x02009;0.0074) had significantly higher risk of developing recurrence. The risk of developing recurrence was significantly higher in the group of patients with high MVD distal resection margin compared with low MVD distal resection margin (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6c</xref>, log-rank test, <italic>p</italic>&#x02009;=&#x02009;0.0211).<table-wrap id="Tab4"><label>Table 4</label><caption><p>The recurrence rates and univariate analysis according to cut-off values for MVD</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variables</th><th>Cut-off value</th><th>Number of patients</th><th>Recurrence rates</th><th>
<italic>p</italic> value*</th></tr></thead><tbody><tr><td>MVD in tumors</td><td/><td/><td/><td>0.0008</td></tr><tr><td/><td>&#x02264;106.2</td><td>24</td><td>37.5</td><td/></tr><tr><td/><td>&#x0003e;106.2</td><td>71</td><td>9.8</td><td/></tr><tr><td>MVD in DRM</td><td/><td/><td/><td>0.0074</td></tr><tr><td/><td>&#x02264;186.3</td><td>82</td><td>12.2</td><td/></tr><tr><td/><td>&#x0003e;186.3</td><td>13</td><td>46.1</td><td/></tr><tr><td>MVD in PRM</td><td/><td/><td/><td>0.0211</td></tr><tr><td/><td>&#x02264;27.8</td><td>22</td><td>31.8</td><td/></tr><tr><td/><td>&#x0003e;27.8</td><td>73</td><td>12.3</td><td/></tr></tbody></table><table-wrap-foot><p>*log-rank test</p></table-wrap-foot></table-wrap><fig id="Fig6"><label>Fig. 6</label><caption><p>Kaplan-Meier curves for recurrence-free survival according to CD105-MVD. <bold>a</bold> CD105-MVD in tumor (cut-off level of MVD 106.2/mm<sup>2</sup>). <bold>b</bold> CD105-MVD in DRM (cut-off level of MVD 186.3&#x000a0;mm<sup>2</sup>). <bold>c</bold> CD105-MVD in PRM (cut-off level MVD 27.8/mm<sup>2</sup>
</p></caption><graphic xlink:href="12957_2016_877_Fig6_HTML" id="MO6"/></fig></p></sec><sec id="Sec11"><title>Multiple Cox regression analysis</title><p>The prognostic variables were determined by Cox proportional hazard regression analysis. The variables: age, gender, type of surgical resection, tumor location, grade of differentiation, histological type, depth of tumor invasion, tumor size, length of the surgical distal and proximal margin, MVD tumors, and MVD of surgical distal and proximal margin were entered into the multivariate model to determine their relation with recurrent tumors. &#x0201c;Backward&#x0201d; analysis was performed. Results of the multivariate analysis are presented in Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref>. The result showed that the type surgery (OR&#x02009;=&#x02009;4.11, <italic>p</italic>&#x02009;=&#x02009;0.0086), MVD tumors (OR&#x02009;=&#x02009;0.33, <italic>p</italic>&#x02009;=&#x02009;0.0385), and MVD of proximal resection margin (OR&#x02009;=&#x02009;0.27, <italic>p</italic>&#x02009;=&#x02009;0.0218) were the independent prognostic factors for recurrent tumors. Tumor size and MVD distal resection margins were on the border of significance.<table-wrap id="Tab5"><label>Table 5</label><caption><p>Cox proportional-hazard regression analysis for tumor recurrence (method &#x0201c;backward&#x0201d;)</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Covariate</th><th>
<italic>p</italic> value</th><th>OR</th><th>(95 % CI)</th></tr></thead><tbody><tr><td>Type of surgery (LAR versus APR)</td><td char="." align="char">0.0086</td><td>4.1103</td><td>1.4397&#x02013;11.7346</td></tr><tr><td>Tumor size (&#x02264;4 versus &#x0003e;4&#x000a0;cm)</td><td char="." align="char">0.0577</td><td>0.3356</td><td>0.1093&#x02013;1.0302</td></tr><tr><td>MVD in tumors (&#x02264;106.2 versus &#x0003e;106.2)</td><td>0.0385</td><td char="." align="char">0.3330</td><td>0.1182&#x02013;0.9384</td></tr><tr><td>MVD in DRM (&#x02264;186.3 versus &#x0003e;186.3)</td><td char="." align="char">0.0537</td><td>2.9359</td><td>0.9885&#x02013;8.7195</td></tr><tr><td>MVD in PRM (&#x02264;27.8 versus &#x0003e;27.8)</td><td char="." align="char">0.0218</td><td>0.2778</td><td>0.0935&#x02013;0.8255</td></tr></tbody></table><table-wrap-foot><p>Overall model fit <italic>&#x003c7;</italic>
<sup>2</sup>&#x02009;=&#x02009;23.20, <italic>p</italic>&#x02009;=&#x02009;0.0003</p><p>
<italic>MVD</italic> microvessel density, <italic>OR</italic> odds ratio, <italic>95 % CI</italic> confidence interval, <italic>DRM</italic> distal resection margin, <italic>PRM</italic> proximal resection margin</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec12"><title>Discussion</title><p>Stage II RC is defined by the presence of penetration through the muscularis propria and the absence of metastasis to either regional lymph nodes or distant sites [<xref ref-type="bibr" rid="CR13">13</xref>]. Rectal cancer surgery is effective for localized disease; however, approximately 25&#x02013;30&#x000a0;% patients with stage II disease are at high risk for postoperative recurrence, and the clinical outcome of these patients is similar to that of patients with stage III disease [<xref ref-type="bibr" rid="CR14">14</xref>]. Identifying high-risk patients with stage II RC is important because it may help to identify patients and additional risk for whom surgery alone may not be a curative treatment. During the past two decades, many clinicopathologic studies indicate the importance of tumor angiogenic activity in defining the aggressiveness of tumor behavior [<xref ref-type="bibr" rid="CR15">15</xref>]. The microvessel density (MVD), which is based on the morphological visualization and quantification of blood vessels, represents a possible prognostic value in colorectal cancer [<xref ref-type="bibr" rid="CR16">16</xref>]. Over the past decade, numerous studies have investigated the value of angiogenesis markers in CRC. Endoglin is a proliferation-associated antigen on endothelial cells and essential for angiogenesis. It has been reported that expression of the endoglin in tumor endothelium may be a prognostic indicator of the outcome for various human tumors including and colorectal cancer (CRC) [<xref ref-type="bibr" rid="CR17">17</xref>]. Many angiogenesis markers have been studied but have not been used in conjunction with the angiogenesis in the surgical resection margins.</p><p>Microvessel density assessment is the most commonly used technique to quantify intra-tumoral angiogenesis in cancer. In the present study, we assessed MVD with CD105 marker in RC tissue, distal resection margin, and proximal resection margin. In our cohort, endoglin microvessel immunostaining was consistently present in all the cases studied. We showed that the CD105-MVD values significantly increase in RC from the proximal and distal resection margin to the primary tumor (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). These results support the role of CD105 as an optimal marker of proliferation of endothelial cells and its potential as prognostic factor [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. In our study, overall 5-year recurrence rate for all patients included in this study was 16.8&#x000a0;%.</p><p>Recurrence rates in our cohort stage II RC patients were analyzed according to age, gender, surgery, tumor location, grade of differentiation, histology, depth of tumor invasion, and tumor size (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). By univariate analysis, only the type of surgical resection was found to be significant prognostic factors for tumor recurrence. Patients treated with a primary APR had a higher rate of tumor recurrence than those who underwent a LAR, which is in accordance with the results of most of the authors [<xref ref-type="bibr" rid="CR19">19</xref>]. Previous studies have demonstrated an LAR to APR ratio 3:1 or 4:1 which is consistent with our results [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. However, most studies were too small to adequately evaluate the relationship between the type surgery and tumor recurrence (TR). The key to successful surgery is complete excision of the tumor with sufficient margin of normal tissue. TR may also sometimes occur even in the absence of an involved CRM possibly owing to lymphatic spread from the distal rectum to lymph nodes in the pelvic side wall [<xref ref-type="bibr" rid="CR21">21</xref>]. In low rectal cancer, total mesorectal excision (TME) surgery may be insufficient to obtain the desired CRM because of lack of mesorectum at the level of the pelvic floor [<xref ref-type="bibr" rid="CR22">22</xref>]. APR surgery frequently results in perineal and presacral TR [<xref ref-type="bibr" rid="CR23">23</xref>]. The choice of surgical resection is limited and influenced by tumor staging, tumor location, and intrapelvic tumor invasion at the time of the diagnosis [<xref ref-type="bibr" rid="CR24">24</xref>].</p><p>Patients with stage II RC have a high risk of developing recurrence of the tumor despite multimodality treatment [<xref ref-type="bibr" rid="CR25">25</xref>]. Although angiogenesis affect the outcome of treatments, the importance of angiogenesis as a prognostic factor is still not clearly enough defined. In the studies, there are considerable differences in microvessel counts in tissue of rectal carcinoma. The quantification of microvessel density was made in the majority of studies with classical Weidner&#x02019;s method [<xref ref-type="bibr" rid="CR11">11</xref>]. In our study, tumor microvessel density was obtained by computerized image analysis.</p><p>For colorectal cancer, conflicting results have been reported on the prognostic importance of MVD in prediction of tumor aggressive behavior in various subsets of patients. Due to inconsistent methods of analysis of tumor angiogenesis in various studies, it is difficult to compare the values of MVD obtained in our analysis with the results of other authors. In our analysis, we found higher values of MVD (CD105-MVD, 221.0/mm<sup>2</sup> on average) in RC tissues in comparison with the results in the study of Svagzdys et al. (CD34-MVD, 193.0/mm<sup>2</sup> on average), possibly due to the larger surface of the analyzed tumor tissue (0.612 versus 0.576/mm<sup>2</sup>) and the use of different endothelial cell markers [<xref ref-type="bibr" rid="CR26">26</xref>]. In the present study, the microvessel counts are high and confirm that the rectal carcinoma is strongly dependent on angiogenesis.</p><p>Furthermore, significantly higher rates of tumor recurrence were found in patients with lower MVD in tumors than in cut-off value obtained by ROC analysis. This is shown by Kaplan-Meier recurrence curve for MVD in RC tissue (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>). Our results suggest that the lower CD105-MVD is accompanied by higher rate of tumor recurrence, which is not in accordance with the results that an increased CD105-MVD was correlated with recurrence of the disease after radical resection. In their study, Skoufi et al. have found a strong association between increased CD105-MVD and recurrence of CRC [<xref ref-type="bibr" rid="CR27">27</xref>]. Chen et al. have reported that the RC with higher MVD are more likely to recur or metastasize after radical resection (CD31 immunostaining, average as cut-off) [<xref ref-type="bibr" rid="CR28">28</xref>]. Other studies demonstrated that high MVD counts determined using CD105 were strongly associated with high risk of metastatic disease (Saad et al., Romani et al., median as cut-off) [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. According to the results in the study of Uribarrena et al., patients with stage I and II colorectal carcinomas with higher vascularized tumor area had a significant association with a better outcome, but no significant relationship was observed between MVD and tumor recurrence and death [<xref ref-type="bibr" rid="CR31">31</xref>]. Some studies reveal that MVD determined with CD105 is not correlated with recurrence rate [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>].</p><p>In the present study, we found a significant inverse correlation between the CD105-MVD in the distal resection margins and the length of DRM that were closest to the RC. This analysis suggested an active reaction of the adjacent mucosa related to the presence of the tumor, but a more passive reaction induced by the factors released from the tumor [<xref ref-type="bibr" rid="CR34">34</xref>]. Also, our result shows a significant correlation between the CD105-MVD and tumor recurrence: significantly higher rates of tumor recurrence were found in patients with higher CD105-MVD in distal resection margins than cut-off value obtained by ROC analysis. Regarding the pattern of recurrence after surgery alone, we revealed that lower CD105-MVD in tumors and higher CD105-MVD in distal resection margins significantly correlated with tumor recurrence, suggesting that CD105 may be involved in developing tumor recurrence in rectal cancer. However, the results of different studies are linking the lower tumor vascularity with poor outcomes and in various other solid tumors [<xref ref-type="bibr" rid="CR35">35</xref>]. Only recently acquired knowledge has led to the conclusions that the local tissue microenvironment contributes significantly to tumor progression.</p><p>We hypothesize that a crosstalk exists between rectal tumor cells and adjacent mucosa of distal margin. Tumor secretes cytokines and other signaling proteins which induce angiogenesis in the adjacent mucosa of distal margin [<xref ref-type="bibr" rid="CR34">34</xref>]. TGF-&#x003b2;1, a multifunctional cytokine, has a complex role in angiogenesis. It is expressed in number of cell types, including endothelial cells, depending on the concentration, is both pro angiogenic and antiangiogenic [<xref ref-type="bibr" rid="CR36">36</xref>]. One molecule that may orchestrate this balance is endoglin [<xref ref-type="bibr" rid="CR37">37</xref>]. Endoglin is an auxiliary membrane receptor for transforming growth factor beta (TGF-&#x003b2;) that modulates TGF-&#x003b2; signaling [<xref ref-type="bibr" rid="CR35">35</xref>]. Recently, endoglin has been identified as a key regulator of tumor cells proliferation, migration, and invasion [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. Craft et al. showed that endoglin expression was lost during prostate cancer cell progression, and that led to increased cell invasion and migration [<xref ref-type="bibr" rid="CR38">38</xref>]. It has been suggested that endoglin deficiency results in angiogenic adaptation, weakens the endothelial barrier, and increased metastatic spread and may be associated with cancer progression [<xref ref-type="bibr" rid="CR39">39</xref>].</p></sec><sec id="Sec13"><title>Conclusions</title><p>In conclusion, this study showed that the CD105-MVD is a useful marker for identifying patients with an aggressive form of stage II RC. CD105-assessed MVD both tumor and adjacent mucosa of distal resection margin could help to identify patients with more aggressive disease and increased risk of developing tumor recurrence after surgical treatment in the group of stage II RC.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>APR</term><def><p>abdominoperineal resection</p></def></def-item><def-item><term>CD105</term><def><p>endoglin</p></def></def-item><def-item><term>CD31</term><def><p>platelet endothelial cell adhesion molecule-1 (PECAM-1)</p></def></def-item><def-item><term>CD34</term><def><p>hematopoietic progenitor cell antigen CD34</p></def></def-item><def-item><term>CRC</term><def><p>colorectal cancer</p></def></def-item><def-item><term>DRM</term><def><p>distal resection margin</p></def></def-item><def-item><term>LAR</term><def><p>low anterior resection</p></def></def-item><def-item><term>MVD</term><def><p>microvessel density</p></def></def-item><def-item><term>PRM</term><def><p>proximal resection margin</p></def></def-item><def-item><term>RC</term><def><p>rectal cancer</p></def></def-item><def-item><term>ROC</term><def><p>receiver operating characteristic</p></def></def-item><def-item><term>TGF &#x003b2;</term><def><p>transforming growth factor beta</p></def></def-item><def-item><term>TME</term><def><p>total mesorectal excision</p></def></def-item><def-item><term>TR</term><def><p>tumor recurrence</p></def></def-item><def-item><term>WHO</term><def><p>World Health Organization</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Competing interests</bold></p><p>The authors declare that they have no competing interests.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>&#x0017d;M made conception, designed and coordinated the study, analyzed data, carried out data interpretation, and drafted the manuscript. DK participated in the conception and design of the study, collected data, and carried out the immunohistological analysis. CM participated in the conception and design study, and in drafting of manuscript. All authors read and approved the final manuscript.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We are grateful to Ozren &#x00160;tanfel and Ivan Da&#x00161;ek for excellent technical assistance.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>PE</given-names></name><name><surname>Womeldorph</surname><given-names>CM</given-names></name><name><surname>Johnson</surname><given-names>EK</given-names></name><name><surname>Maykel</surname><given-names>JA</given-names></name><name><surname>Brucher</surname><given-names>B</given-names></name><name><surname>Stojadinovic</surname><given-names>A</given-names></name><name><surname>Avital</surname><given-names>I</given-names></name><name><surname>Nissan</surname><given-names>A</given-names></name><name><surname>Steele</surname><given-names>SR</given-names></name></person-group><article-title>Early detection of colorectal cancer recurrence in patients undergoing surgery with curative intent: current status and challenges</article-title><source>J Cancer</source><year>2014</year><volume>5</volume><fpage>262</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.7150/jca.7988</pub-id><pub-id pub-id-type="pmid">24790654</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peeters</surname><given-names>KC</given-names></name><name><surname>Marijnen</surname><given-names>CA</given-names></name><name><surname>Nagtegaal</surname><given-names>ID</given-names></name><name><surname>Kranenbarg</surname><given-names>EK</given-names></name><name><surname>Putter</surname><given-names>H</given-names></name><name><surname>Wiggers</surname><given-names>T</given-names></name><name><surname>Rutten</surname><given-names>H</given-names></name><name><surname>Pahlman</surname><given-names>L</given-names></name><name><surname>Glimelius</surname><given-names>B</given-names></name><name><surname>Leer</surname><given-names>JW</given-names></name><name><surname>van de Velde</surname><given-names>CJ</given-names></name><collab>Dutch Colorectal Cancer Group</collab></person-group><article-title>The TME trial after median follow-up of 6 years: increased local control but no survival in patient treated with chemoradiation and mesorectal excision for rectal cancer</article-title><source>Ann Surg</source><year>2007</year><volume>246</volume><fpage>693</fpage><lpage>701</lpage><pub-id pub-id-type="doi">10.1097/01.sla.0000257358.56863.ce</pub-id><pub-id pub-id-type="pmid">17968156</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basu</surname><given-names>S</given-names></name><name><surname>Srivastava</surname><given-names>V</given-names></name><name><surname>Shukla</surname><given-names>VK</given-names></name></person-group><article-title>Recent advances in the management of carcinoma of the rectum</article-title><source>Clin Exp Gastroenterol</source><year>2009</year><volume>2</volume><fpage>49</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.2147/CEG.S4778</pub-id><pub-id pub-id-type="pmid">21694827</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glyinne-Jones</surname><given-names>R</given-names></name></person-group><article-title>Do T3 rectal cancer always need radiochemotherapy?</article-title><source>Recent Results Cancer Res</source><year>2014</year><volume>203</volume><fpage>95</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1007/978-3-319-08060-4_9</pub-id><pub-id pub-id-type="pmid">25103002</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waserberg</surname><given-names>N</given-names></name><name><surname>Gutman</surname><given-names>H</given-names></name></person-group><article-title>Resection margins in modern rectal cancer surgery</article-title><source>J Surg Oncol</source><year>2008</year><volume>96</volume><fpage>611</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1002/jso.21036</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oklu</surname><given-names>R</given-names></name><name><surname>Walker</surname><given-names>TG</given-names></name><name><surname>Wicky</surname><given-names>S</given-names></name><name><surname>Hesketh</surname><given-names>R</given-names></name></person-group><article-title>Angiogenesis and current antiangiogenic strategies for the treatment cancer</article-title><source>J Vasc Interv Radiol</source><year>2010</year><volume>21</volume><fpage>1791</fpage><lpage>805</lpage><pub-id pub-id-type="doi">10.1016/j.jvir.2010.08.009</pub-id><pub-id pub-id-type="pmid">20980167</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marioni</surname><given-names>G</given-names></name><name><surname>Staffiery</surname><given-names>A</given-names></name><name><surname>Manzato</surname><given-names>E</given-names></name><name><surname>Ralli</surname><given-names>G</given-names></name><name><surname>Lionello</surname><given-names>M</given-names></name><name><surname>Giacomelli</surname><given-names>L</given-names></name><name><surname>Prosenikliev</surname><given-names>V</given-names></name><name><surname>Marchese-Ragona</surname><given-names>R</given-names></name><name><surname>Busnardo</surname><given-names>A</given-names></name><name><surname>Bolzetta</surname><given-names>F</given-names></name><name><surname>Blandamura</surname><given-names>S</given-names></name></person-group><article-title>A higher CD105-assessed microvessel density and vorse prognosis in elderly patients with laryngeal carcinoma</article-title><source>Arch Otolaryngol Head Neck Surg</source><year>2011</year><volume>137</volume><fpage>175</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1001/archoto.2010.244</pub-id><pub-id pub-id-type="pmid">21339405</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fonsatti</surname><given-names>E</given-names></name><name><surname>Nicolay</surname><given-names>HJM</given-names></name><name><surname>Altamonte</surname><given-names>M</given-names></name><name><surname>Covre</surname><given-names>A</given-names></name><name><surname>Maio</surname><given-names>M</given-names></name></person-group><article-title>Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours</article-title><source>Cardiovasc Res</source><year>2010</year><volume>86</volume><fpage>12</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvp332</pub-id><pub-id pub-id-type="pmid">19812043</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="other">Edge SB, Byrd DR, Compton CC, Fritz AG, Green FL, Trotti A, Eds. AJCC: colon and rectum in AJCC Cancer Staging Manual. 7th edition. New York, NY USA: Springer; 2010. p. 143&#x02013;64.</mixed-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barresi</surname><given-names>V</given-names></name><name><surname>Bonetti</surname><given-names>LR</given-names></name><name><surname>Ieni</surname><given-names>A</given-names></name><name><surname>Branca</surname><given-names>G</given-names></name><name><surname>Baron</surname><given-names>L</given-names></name><name><surname>Tuccari</surname><given-names>G</given-names></name></person-group><article-title>Histologic grading based on counting poorly differentiated clusters in preoperative biopsy predict nodal involvement and pTNM stage in colorectal cancer patients</article-title><source>Hum Pathol</source><year>2014</year><volume>45</volume><fpage>268</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1016/j.humpath.2013.07.046</pub-id><pub-id pub-id-type="pmid">24289972</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weidner</surname><given-names>N</given-names></name><name><surname>Semple</surname><given-names>JP</given-names></name><name><surname>Welch</surname><given-names>WR</given-names></name><name><surname>Folkman</surname><given-names>J</given-names></name></person-group><article-title>Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma</article-title><source>N Engl J Med</source><year>1991</year><volume>324</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1056/NEJM199101033240101</pub-id><pub-id pub-id-type="pmid">1701519</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>S&#x001ff;reide</surname><given-names>K</given-names></name></person-group><article-title>Receiver-operating characteristic curve analysis in diagnostic, prognostic and predictive biomarker research</article-title><source>J Clin Pathol</source><year>2009</year><volume>62</volume><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1136/jcp.2008.061010</pub-id><pub-id pub-id-type="pmid">18818262</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Compton</surname><given-names>CC</given-names></name></person-group><article-title>Optimal pathological staging: defining stage II disease</article-title><source>Clin Cancer Res</source><year>2007</year><volume>13</volume><fpage>6862s</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-1398</pub-id><pub-id pub-id-type="pmid">18006791</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeh</surname><given-names>Y-S</given-names></name><name><surname>Wang</surname><given-names>H-M</given-names></name><name><surname>Lin</surname><given-names>S-R</given-names></name></person-group><article-title>Prognostic and molecular factors in stage II colorectal cancer</article-title><source>Genomic Med Biomark Health Sci</source><year>2011</year><volume>3</volume><fpage>2</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/S2211-4254(11)60002-2</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guetz</surname><given-names>GD</given-names></name><name><surname>Uzzan</surname><given-names>B</given-names></name><name><surname>Nicolas</surname><given-names>P</given-names></name><name><surname>Cucherat</surname><given-names>M</given-names></name><name><surname>Morere</surname><given-names>J-F</given-names></name><name><surname>Benamouzig</surname><given-names>R</given-names></name><name><surname>Breau</surname><given-names>J-L</given-names></name><name><surname>Perret</surname><given-names>G-Y</given-names></name></person-group><article-title>Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literatur<bold>e</bold></article-title><source>Br J Cancer</source><year>2006</year><volume>94</volume><fpage>1823</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6603176</pub-id><pub-id pub-id-type="pmid">16773076</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Knutsen</surname><given-names>A</given-names></name><name><surname>Arbman</surname><given-names>G</given-names></name><name><surname>Carstensen</surname><given-names>J</given-names></name><name><surname>Fernlund</surname><given-names>B</given-names></name><name><surname>Sun</surname><given-names>XF</given-names></name></person-group><article-title>Clinical and biological significance of angiogenesis and lymphangiogenesis in colorectal cancer</article-title><source>Dig Liver Dis</source><year>2009</year><volume>41</volume><fpage>116</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.dld.2008.07.315</pub-id><pub-id pub-id-type="pmid">19038587</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nassiri</surname><given-names>F</given-names></name><name><surname>Cusimano</surname><given-names>MD</given-names></name><name><surname>Scheithauer</surname><given-names>BW</given-names></name><name><surname>Rotondo</surname><given-names>F</given-names></name><name><surname>Fazio</surname><given-names>A</given-names></name><name><surname>Yousef</surname><given-names>GM</given-names></name><name><surname>Syro</surname><given-names>LV</given-names></name><name><surname>Kovacs</surname><given-names>K</given-names></name><name><surname>Lloyd</surname><given-names>RV</given-names></name></person-group><article-title>Endoglin (CD105): a review of its role in angiogenesis and tumor diagnosis, progression and therapy</article-title><source>Anticancer Res</source><year>2011</year><volume>31</volume><fpage>2283</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">21737653</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fox</surname><given-names>SH</given-names></name><name><surname>Whalen</surname><given-names>GF</given-names></name><name><surname>Sanders</surname><given-names>MM</given-names></name><name><surname>Burleson</surname><given-names>JA</given-names></name><name><surname>Jennings</surname><given-names>K</given-names></name><name><surname>Kurtzman</surname><given-names>S</given-names></name><name><surname>Kreutzer</surname><given-names>D</given-names></name></person-group><article-title>Angiogenesis in normal tissue adjacent to colon cancer</article-title><source>J Surg Oncol</source><year>1998</year><volume>69</volume><fpage>230</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1096-9098(199812)69:4&#x0003c;230::AID-JSO7&#x0003e;3.0.CO;2-Q</pub-id><pub-id pub-id-type="pmid">9881940</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X-T</given-names></name><name><surname>Li</surname><given-names>D-G</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Kong</surname><given-names>F-B</given-names></name><name><surname>Pang</surname><given-names>L-M</given-names></name><name><surname>Mai</surname><given-names>W</given-names></name></person-group><article-title>Mata-analysis of oncological outcome after abdominoperineal resection or low anterior resection for lower rectal cancer</article-title><source>Pathol Oncol Res</source><year>2015</year><volume>21</volume><fpage>19</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1007/s12253-014-9863-x</pub-id><pub-id pub-id-type="pmid">25430561</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perry</surname><given-names>WB</given-names></name><name><surname>Connaughton</surname><given-names>JC</given-names></name></person-group><article-title>Abdominoperineal resection: how is it done and wath are results?</article-title><source>Clin Colon Rectal Surg</source><year>2007</year><volume>20</volume><issue>3</issue><fpage>213</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1055/s-2007-984865</pub-id><pub-id pub-id-type="pmid">20011202</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moriya</surname><given-names>Y</given-names></name><name><surname>Sugihara</surname><given-names>K</given-names></name><name><surname>Akasu</surname><given-names>T</given-names></name><name><surname>Fujita</surname><given-names>S</given-names></name></person-group><article-title>Patterns of recurrence after nerve-sparing surgery for rectal adenocarcinoma with special reference to loco-regional recurrence</article-title><source>Dis Colon Rectum</source><year>1995</year><volume>38</volume><fpage>1162</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1007/BF02048331</pub-id><pub-id pub-id-type="pmid">7587758</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bujanda</surname><given-names>L</given-names></name></person-group><article-title>Patterns of local recurrence in rectal cancer after a multidisciplinary approach</article-title><source>World J Gastroenterol</source><year>2011</year><volume>17</volume><fpage>1674</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.3748/wjg.v17.i13.1674</pub-id><pub-id pub-id-type="pmid">21483626</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>West</surname><given-names>NP</given-names></name><name><surname>Anderin</surname><given-names>C</given-names></name><name><surname>Smith</surname><given-names>KJ</given-names></name><name><surname>Holm</surname><given-names>T</given-names></name><name><surname>Quirke</surname><given-names>P</given-names></name></person-group><article-title>Multicentre experience with extralevator abdominoperineal excision for low rectal cancer</article-title><source>Br J Surg</source><year>2010</year><volume>97</volume><fpage>588</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1002/bjs.6916</pub-id><pub-id pub-id-type="pmid">20186891</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Gu</surname><given-names>X</given-names></name><name><surname>Fang</surname><given-names>Y</given-names></name><name><surname>Xiang</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name></person-group><article-title>Prognostic factors associated with locally recurrent rectal cancer following primary surgery (review)</article-title><source>Oncol Lett</source><year>2014</year><volume>7</volume><fpage>10</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">24348812</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>TD</given-names></name><name><surname>Fakih</surname><given-names>MG</given-names></name><name><surname>Yang</surname><given-names>GY</given-names></name></person-group><article-title>Management of stage II/III rectal cancer</article-title><source>J Gastrointest Oncol</source><year>2010</year><volume>1</volume><fpage>112</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">22811815</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Svagzdys</surname><given-names>S</given-names></name><name><surname>Lesauskaite</surname><given-names>V</given-names></name><name><surname>Pavalkis</surname><given-names>D</given-names></name><name><surname>Nedzinskiene</surname><given-names>I</given-names></name><name><surname>Pranys</surname><given-names>D</given-names></name><name><surname>Tamelis</surname><given-names>A</given-names></name></person-group><article-title>Microvessel density as new prognostic marker after radiotherapy in rectal cancer</article-title><source>BMC Cancer</source><year>2009</year><volume>9</volume><fpage>95</fpage><pub-id pub-id-type="doi">10.1186/1471-2407-9-95</pub-id><pub-id pub-id-type="pmid">19323831</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skoufi</surname><given-names>U</given-names></name><name><surname>Arvanitis</surname><given-names>LD</given-names></name><name><surname>Lamprey</surname><given-names>L</given-names></name><name><surname>Ioachirn</surname><given-names>E</given-names></name><name><surname>Koutsogiannis</surname><given-names>J</given-names></name><name><surname>Skoufi</surname><given-names>C</given-names></name><name><surname>Tsironis</surname><given-names>D</given-names></name><name><surname>Mitselou</surname><given-names>A</given-names></name></person-group><article-title>Association of claudin-1 with E-cadherin/catenin complex, microvessel density (MVD)-related markers, and clinicopathological features in colorectal carcinoma</article-title><source>J Interdiscipl Histopathol</source><year>2014</year><volume>2</volume><fpage>135</fpage><lpage>44</lpage></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>YB</given-names></name><name><surname>Wan</surname><given-names>DS</given-names></name><name><surname>Zhan</surname><given-names>YQ</given-names></name><name><surname>Zhou</surname><given-names>ZW</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name></person-group><article-title>Correlation of tumor microvessel density to metastasis and recurrence of rectal cancer</article-title><source>Ai Zheng</source><year>2004</year><volume>23</volume><fpage>1203</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">15473936</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saad</surname><given-names>RS</given-names></name><name><surname>Liu</surname><given-names>YL</given-names></name><name><surname>Nathan</surname><given-names>G</given-names></name><name><surname>Celebrezze</surname><given-names>J</given-names></name><name><surname>Medich</surname><given-names>D</given-names></name><name><surname>Silverman</surname><given-names>J</given-names></name></person-group><article-title>Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in colorectal cancer</article-title><source>Mod Pathol</source><year>2004</year><volume>17</volume><fpage>197</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1038/modpathol.3800034</pub-id><pub-id pub-id-type="pmid">14657950</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romani</surname><given-names>AA</given-names></name><name><surname>Borghetti</surname><given-names>AF</given-names></name><name><surname>Del Rio</surname><given-names>P</given-names></name><name><surname>Sianesi</surname><given-names>M</given-names></name><name><surname>Soliani</surname><given-names>P</given-names></name></person-group><article-title>The risk of developing metastatic disease in colorectal cancer is related to CD105-positive vessel count</article-title><source>J Surg Oncol</source><year>2006</year><volume>93</volume><fpage>446</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1002/jso.20456</pub-id><pub-id pub-id-type="pmid">16615157</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uribarrena</surname><given-names>AR</given-names></name><name><surname>Ortego</surname><given-names>J</given-names></name><name><surname>Fuentes</surname><given-names>J</given-names></name><name><surname>Ravent&#x000f3;s</surname><given-names>N</given-names></name><name><surname>Parra</surname><given-names>P</given-names></name><name><surname>Uribarrena</surname><given-names>ER</given-names></name></person-group><article-title>Prognostic value of microvascular density in Duke A and B (T1-T4, N0, M0) colorectal carcinomas</article-title><source>Gastroenterol Res Pract</source><year>2009</year><volume>2009</volume><fpage>Article ID 679830</fpage><pub-id pub-id-type="doi">10.1155/2009/679830</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pietra</surname><given-names>N</given-names></name><name><surname>Sarli</surname><given-names>L</given-names></name><name><surname>Caruana</surname><given-names>P</given-names></name><name><surname>Cabras</surname><given-names>A</given-names></name><name><surname>Costi</surname><given-names>R</given-names></name><name><surname>Gobbi</surname><given-names>S</given-names></name><name><surname>Bordi</surname><given-names>C</given-names></name><name><surname>Peracchia</surname><given-names>A</given-names></name></person-group><article-title>In tumor angiogenesis a prognostic factor in patients with colorectal cancer and no involved nodes?</article-title><source>Eur J Surg</source><year>2000</year><volume>166</volume><fpage>552</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1080/110241500750008628</pub-id><pub-id pub-id-type="pmid">10965834</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>TF</given-names></name><name><surname>Kjaer-Frifeldt</surname><given-names>S</given-names></name><name><surname>Morgenthaler</surname><given-names>S</given-names></name><name><surname>Blondal</surname><given-names>T</given-names></name><name><surname>Lindebjerg</surname><given-names>J</given-names></name><name><surname>Jakobsen</surname><given-names>A</given-names></name><name><surname>S&#x001ff;rensen</surname><given-names>B</given-names></name></person-group><article-title>The prognostic value of microRNA-126 and microvessel density in patients with stage II colon cancer: results from a population cohort</article-title><source>J Transl Med</source><year>2014</year><volume>12</volume><fpage>254</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1186/s12967-014-0254-6</pub-id><pub-id pub-id-type="pmid">25199818</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanz-Pamplona</surname><given-names>R</given-names></name><name><surname>Berenguer</surname><given-names>A</given-names></name><name><surname>Cordero</surname><given-names>D</given-names></name><name><surname>Mollevi</surname><given-names>DG</given-names></name><name><surname>Crous-Bou</surname><given-names>M</given-names></name><name><surname>Sole</surname><given-names>X</given-names></name><name><surname>Per&#x000e9;-Brunet</surname><given-names>L</given-names></name><name><surname>Gueno</surname><given-names>E</given-names></name><name><surname>Salazar</surname><given-names>R</given-names></name><name><surname>Santos</surname><given-names>C</given-names></name><name><surname>De Oca</surname><given-names>J</given-names></name><name><surname>Sanjuan</surname><given-names>X</given-names></name><name><surname>Rodriguez-Moranta</surname><given-names>F</given-names></name><name><surname>Moreno</surname><given-names>V</given-names></name></person-group><article-title>Aberrant gene expression in mucosa adjacent to tumor reveals a molecular crosstalk in colon cancer</article-title><source>Mol Cancer</source><year>2014</year><volume>13</volume><fpage>46</fpage><pub-id pub-id-type="doi">10.1186/1476-4598-13-46</pub-id><pub-id pub-id-type="pmid">24597571</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>P&#x000e9;rez-G&#x000f3;mez</surname><given-names>E</given-names></name><name><surname>del Castillo</surname><given-names>G</given-names></name><name><surname>Santib&#x000e1;&#x00148;ez</surname><given-names>JF</given-names></name><name><surname>L&#x000f3;pez-Novoa</surname><given-names>JM</given-names></name><name><surname>Bernab&#x000e9;u</surname><given-names>C</given-names></name><name><surname>Quintanilla</surname><given-names>M</given-names></name></person-group><article-title>The role of the TGF-&#x003b2; coreceptor endoglin in cancer</article-title><source>Scientific World J</source><year>2010</year><volume>10</volume><fpage>2367</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1100/tsw.2010.230</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goel</surname><given-names>S</given-names></name><name><surname>Duda</surname><given-names>DG</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Munn</surname><given-names>LL</given-names></name><name><surname>Boucher</surname><given-names>Y</given-names></name><name><surname>Fukumura</surname><given-names>D</given-names></name><name><surname>Jain</surname><given-names>RK</given-names></name></person-group><article-title>Normalisation of the vasculature for treatment of cancer and other disease</article-title><source>Physiol Rev</source><year>2011</year><volume>91</volume><fpage>1071</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1152/physrev.00038.2010</pub-id><pub-id pub-id-type="pmid">21742796</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jain</surname><given-names>RK</given-names></name></person-group><article-title>Molecular regulation vessel maturation</article-title><source>Nat Med</source><year>2003</year><volume>9</volume><fpage>685</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1038/nm0603-685</pub-id><pub-id pub-id-type="pmid">12778167</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Craft</surname><given-names>CS</given-names></name><name><surname>Romero</surname><given-names>D</given-names></name><name><surname>Vary</surname><given-names>CPH</given-names></name><name><surname>Bergan</surname><given-names>RC</given-names></name></person-group><article-title>Endoglin inhibits prostate cancer motility via activation of the ALK2-Smad1 pathway</article-title><source>Oncogene</source><year>2007</year><volume>26</volume><fpage>7240</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1210533</pub-id><pub-id pub-id-type="pmid">17496924</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderberg</surname><given-names>C</given-names></name><name><surname>Cunha</surname><given-names>SI</given-names></name><name><surname>Zhai</surname><given-names>Z</given-names></name><name><surname>Cortez</surname><given-names>E</given-names></name><name><surname>Pardali</surname><given-names>E</given-names></name><name><surname>Johnson</surname><given-names>JR</given-names></name><name><surname>Franco</surname><given-names>M</given-names></name><name><surname>P&#x000e1;ez-Ribes</surname><given-names>M</given-names></name><name><surname>Cordiner</surname><given-names>R</given-names></name><name><surname>Fuxe</surname><given-names>J</given-names></name><name><surname>Johansson</surname><given-names>BR</given-names></name><name><surname>Goumans</surname><given-names>M-J</given-names></name><name><surname>Casanovas</surname><given-names>O</given-names></name><name><surname>ten Dijke</surname><given-names>P</given-names></name><name><surname>Arthur</surname><given-names>HM</given-names></name><name><surname>Pietras</surname><given-names>K</given-names></name></person-group><article-title>Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination</article-title><source>J Exp Med</source><year>2013</year><volume>210</volume><fpage>563</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1084/jem.20120662</pub-id><pub-id pub-id-type="pmid">23401487</pub-id></element-citation></ref></ref-list></back></article>
